Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Knowing what to look for and how to manage the changes can make a difference. Secondary progressive MS (SPMS) can affect both physical health and cognitive abilities. Results from a small 2025 ...

A new study reveals that mitochondrial dysfunction plays a central role in the loss of Purkinje neurons in the cerebellum, ...

Enrollment is now complete in two Phase 3 clinical trials testing vidofludimus calcium in adults with relapsing forms of ...

"With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...

Shares of Tiziana Life Sciences climbed after the company said it has expanded a Phase 2 clinical trial that is underway of its treatment for multiple sclerosis, an autoimmune condition that affects ...

Multiple sclerosis is a long-term autoimmune disorder in which the immune system mistakenly attacks the protective sheath ...